NIPT and Next Generation Sequencing

Maternal plasma contains cell-free DNA from both mother and fetus. Next Generation Sequencing (NGS) of maternal plasma cell-free DNA allows fast and safe non-invasive prenatal testing (NIPT) for the screening of fetal aneuploidies: trisomy and monosomy. It is also possible to detect small copy number abnormalities (CNAs) like sub-chromosomal deletions or duplications and to determine the fetal sex.

A trisomy is characterized by the presence of three instances of a particular chromosome, instead of the normal two. With NGS, it is defined by an increase of reads aligned on this particular chromosome compared to the other.

Aneuploidies detection

The detection of fetal aneuploidies is based on a combination of high quality alignments against the human genome and read counts to identify chromosomal gain or loss. Different normalization are performed based on sequenced reads GC percentage to calculate high-quality z-scores.

The presence of a fetal aneuploidy is assessed by the value of three z-score calculations and some quality criterion computed for each samples: reads GC content, reads quality and number...


Small CNAs detection

The detection of small CNAs depends on a count analysis. Chromosomes are cut into bins and reads are counted. A z-score is computed to compare all chromosome bins representation. During z-score computation a normalization based on bins' reads GC percentage is performed. Finally, in order to eliminate the background noise, a deconvolution step is added to improve the detection of small CNA.

Fetal Fraction

The fetal fraction of plasma sample is of critical value for interpreting NIPT results. According to the sequencing method, the fetal fraction can be estimated by our solution. Our tool is also able to use an external fetal fraction estimation based on other experimental methods.

Why choose Prena LifePipe®?

Modular

Prena LifePipe® can be associated with different Life and Soft solutions to improve the diagnostic experience.

Built for diagnosis

You can analyze your sequencing results obtained by different sequencing technologies and platforms to detect karyotypic abnormalities and assess their fetal or maternal origins.

Quality

Our developments follow a strict quality process in accordance with ISO 62304 recommendations. The target date for CE marking is 2019.

Easy to deploy

Prena LifePipe® makes use of Docker® technology to allow quick and easy deployment onto your IT infrastructure.

A modular solution

Our bioinformatics pipeline can be easily integrated with other tools to improve the analysis experience. For example, Micro LifePipe® can detects DNA viruses circulating in maternal plasma that would be important for a fetus’ development.

Contact Us

Ask about our offer, find answers to your questions and get in touch.